Incretins and Their Analogues as New Antidiabetic Drugs

Drug News and Perspectives

Volumn 16, Issue 7, 2003, Pages 413-422

  Nauck, Michael A ^a   Meier, Juris J ^b   Creutzfeldt, Werner ^c  

^a DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CJC 1311; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; LY 307161; UNCLASSIFIED DRUG;

ANOREXIA; CELL DIFFERENTIATION; DRUG ABSORPTION; DRUG DEGRADATION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GROWTH STIMULATION; HUMAN; HYPERGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PHENOTYPE; PROTEIN DEGRADATION; REGENERATION; REVIEW; SATIETY; STOMACH EMPTYING; VOMITING; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0344549608     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.7.829353     Document Type: Review

References (119)

1. Creutzfeldt, W. The incretin concept today. Diabetologia 1979, 16: 75-85.
2. Creutzfeldt, W. and Nauck, M. Gut hormones and diabetes mellitus. Diabetes Metab Rev 1992, 8: 149-77.
3. Brown, J.C. Gastric Inhibitory Polypeptide. Springer-Verlag, Heidelberg, 1982.
4. Schmidt, W.E., Siegel, E.G. and Creutzfeldt, W. Glucagon-like peptide I but not glucagon-like peptide 2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985, 28: 704-7.
5. Kreymann, B., Williams, G., Ghatei, M.A. and Bloom, S.R. Glucagon-like peptide-I [7-36]: A physiological incretin in man. Lancet 1987, 2: 1300-4.
6. Nauck, M.A., Schmidt, W.E., Ebert, R. et al. Insulinotropic properties of synthetic gastric inhibitory peptide in man: Interactions with glucose, phenylalanine, and cholezystokinin-8. J Clin Endocrinol Metab 1989, 69: 654-62.
7. Nauck, M.A., Bartels, E., Ørskov, C., Ebert, R. and Creutzfeldt, W. Additive insulino-tropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993, 76: 912-7.
8. Amland, P.F., Jorde, R., Aanderup, S., Burhol, P.G. and Giercksky, K.-E. Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scand J Gastroenterol 1985, 20: 315-20.
9. Jones, I.R., Owens, D.R., Moody, A.J., Luzio, S.D., Morris, T. and Hayes, T.M. The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 1987, 30: 707-12.
10. Krarup, T., Saurbrey, N., Moody, A.J., Kühl, C. and Madsbad, S. Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. Metabolism 1988, 36: 677-82.
11. Nauck, M.A., Heimesaat, M.M., Ørskov, C., Holst, J.J., Ebert, R. and Creutzfeldt, W. Preserved incretin activity of glucagon-like peptide I [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91: 301-7.
12. Meier, J.J., Hücking, K., Holst, J.J., Deacon, C.F., Schmiegel, W.H. and Nauck, M.A. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes, Diabetes 2001, 50: 2497-504.
13. Lynn, F.C., Pamir, N., Ng, E.H., McIntosh, C.H., Kieffer, T.J. and Pederson, R.A. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001, 50: 1004-11.
14. Krarup, T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev 1988, 9: 122-33.
15. Jones, I.R., Owens, D.R., Luzio, S., Williams, S. and Hayes, T.M. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989, 32: 668-77.
16. Lund, P.K., Goodman, R.H., Dee, P.C. and Habener, J.F. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci USA 1982, 79: 345-9.
17. Bell, G.I., Sanchez-Pescador, R., Laybourn, P.J. and Najarian, R.C. Exon duplication and divergence in the human preproglucagon gene. Nature 1983, 304: 368-71.
18. Ørskov, C., Knuhtsen, S., Baldissera, F.G., Poulsen, S.S., Nielsen, O.V. and Holst, J.J. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986, 119: 1467-75.
19. Ørskov, C., Holst, J.J., Seier-Poulsen, S. and Kirkegaard, P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987, 30: 874-81.
20. Ørskov, C., Bersani, M., Johnsen, A.H., Hojrup, P. and Holst, J.J. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem 1989, 264: 12826-9.
21. Holst, J.J., Ørskov, C., Vagn-Nielsen, O. and Schwartz, T.W. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 1987, 211: 169-74.
22. Mojsov, S., Weir. G.C. and Habener, J.F. Insulinotropin: Glucagon-like peptide 1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987, 79: 616-9.
23. Nauck, M.A., Homberger, E., Siegel, E.G. et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986, 63: 492-8.
24. Shuster, L.T., Go, V.L.W., Rizza, R.A., O'Brien, P.C. and Service, F.J. Incretin effect due to increased secretion and decreased clearance of insuIin in normal humans. Diabetes 1988, 37: 200-3.
25. Ørskov, C., Holst, J.J. and Nielsen, O.V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988, 123: 2009-13.
26. Nathan, D.M., Schreiber, E., Fogel, H., Mojsov, S. and Habener, J.F. Insulinotropic action of glucagon-like peptide 1 (7-37) it diabetic and non-diabetic subjects. Diabetes Care 1992, 15: 270-6.
27. Creutzfeldt, W.O., Kleine, N., Willms, B., Ørskov, C., Holst, J.J. and Nauck, M.A. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996, 19: 580-6.
28. Nauck, M.A., Kleine, N., Ørskov, C., Holst, J.J., Willms, B. and Creutzfeldt, W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 741-4.
29. Flint, A., Raben, A., Astrup, A. and Holst, J.J. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101: 515-20.
30. Gutzwiller, J.P., Göke, B., Drewe, J. et al. Glucagon-like peptide-1 is a physiologic regulator of food intake in humans. Gastroenterol 1997, 112(Suppl.): A1153.
31. Toft-Nielsen, M.-B., Madsbad, S. and Holst, J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22: 1137-43.
32. Zander, M., Madsbad, S., Madsen. J.L. and Holst, J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002, 359: 824-30.
33. Ørskov, C., Poulsen, S.S., Moller, M. and Holst. J.J. Glucagon-like peptide I receptors in the subfornicaI organ and the area postrema are accessible to circulating glucagon-like peptide 1. Diabetes 1996, 45: 832-5.
34. Wettergren, A., Schjoldager, B., Mortensen, P.E., Myhre, J., Christiansen, J. and Holst, J.J. Truncated GLP-I (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993, 38: 665-73.
35. Willms B., Werner, J., Holst, J.J., Ørskov, C., Creutzfeldt, W. and Nauck, M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of erogenotis glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996, 81: 327-32.
36. Nauck, M.A., Niedereichholz, U., Ettler, R. et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997, 273: E981-8.
37. Nauck. M.A. Is glucagon-like peptide 1 an incretin hormone? Diabetologia 1999, 42: 373-9.
38. Fehmann, H.C., Gherzi, R. and Göke, B. Regulation of islet hormone gene expression by incretin hormones. Exp Clin Endocrinol Diabetes 1995, 103(Suppl. 2): 56-65.
39. Perfetti, R., Zhou, J., Doyle, M.E. and Egan, J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141: 4600-5.
40. Wang, X., Zhou, J., Doyle, M.E. and Egan, J.M. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 2001, 142: 1820-7.
41. Nauck, M.A., Wollschläger, D., Wemer, J. et al. Effects of subcutaneous glucagon-like peptide I (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996, 39: 1546-53.
42. Nauck, M.A., Weber, I., Bach, I. et al. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] of [7-37]) in type 2-diabetic patient. Diabetic Med 1998, 15: 937-45.
43. Rachman, J., Gribble, EM., Levy, J.C. and Turner, R.C. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 1997, 40: 205-11.
44. Nauck, M.A., Holst, J.J., Willms, B. and Schmiegel, W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 1997, 105: 187-95.
45. Toft-Nielsen, M., Damholt, M.B., Hilsted, L. et al. GLP-1 secretion is decreased in NIDDM patients compared to matched control subjects with normal glucose tolerance (abstract). Diabetologia 1999, Supplement A40.
46. Toft-Nielsen, M.B., Damholt, M.B., Madsbad, S. et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001, 86: 3717-23.
47. Vilsbøll, T., Krarup, T., Deacon, C.F., Madsbad, S. and Holst, J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide I in type 2 diabetic patients. Diabetes 2001, 50: 609-13.
48. Deacon, C.F., Pridal, L., Klarskov, L., Olesen, M. and Holst, J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996, 271: E458-64.
49. Mentlein, R., Gallwitz, B. and Schmidt, W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory, polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214: 829-35.
50. Knudsen, L.B. and Pridal, L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996, 318: 429-35.
51. Deacon, C.F., Hughes, T.E. and Holst, J.J. GLP-1 [9-36 amide] neither affects insulin release nor antagonises the insulinotropic effects of GLP-1 [7-36 amide] (abstract). Diabetologia 1999, 42: A198.
52. Deacon, C.F., Nauck, M.A., Toft-Nielsen, M., Pridal, L., Willms, B. and Holst, J.J. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 1995, 44: 1126-31.
53. Gutniak, M.K., Linde, B., Holst, J.J. and Efendic, S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 1994, 17: 1039-44.
54. Ritzel, R., Ørskov, C., Holst, J.J. and Nauck, M.A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995, 38: 720-5.
55. Nauck, M.A., Holst, J.J. and Willms, B. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 1997, 29: 411-6.
56. Larsen, J. and Damsbo, P. GLP-1 must be present continuously in order to obtain a good glycaemic control in NIDDM (abstract), Diabetes 1997, 46(Suppl. 1): 186A.
57. Van den Berghe, G., Wouters, P., Weekers, F. et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345: 1359-67.
58. Knudsen, L.B., Nielsen, P.F., Huusfeldt, P.O. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000, 43: 1664-9.
59. Gallwitz, B., Witt, M., Morys-Wortmann, C., Fölsch, U.R. and Schmidt, W.E. GLP-1/GIP chimeric peptides define the structural requirement for specific ligand-receptor interaction of GLP-1. Regul Pept 1996, 63:17-22.
60. Hoffman, J., Chou. J., Myers, S. and Williams, V. LY307161: A fully active, DPP-IV resistant analogue of GLP-1 (abstract). Diabetologia 2000, 43(Suppl. 1): A145.
61. Deacon, C.F., Knudsen, L.B., Madsen, K., Wiberg, EC., Jacobson, O. and Holst, J.J. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998, 41: 271-8.
62. Thorens, B. Expression cloning of the pancreatic beta cell receptor for the glucoincretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992, 89: 8641-5.
63. Thorens, B., Porret, A., Buhler, L., Deng, S.P., Morel, P. and Widmann, C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42: 1678-82.
64. Aaersø, H., Jensen, L.B., Elbrønd, B., Rolan, P. and Zdravkovic, M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45: 195-202.
65. Juhl, C.B., Hollingdal, M., Sturis, J. et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002, 51: 424-9.
66. Matthews, D., Madsbad, S., Schmitz, O., Langendorf, K.W. and Jakobsen, G. The long-acting GLP-1 derivative, NN2211, a new agent for the treatment of type 2 diabetes (abstract). Diabetes 2002, 51 (Suppl, 2): A84.
67. Göke, R., Fehmann, H.C., Linn, T et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993, 268: 19650-5.
68. Kim, D., Taylor, K., Bicsak, T. et al. Subcutaneous injection of AC 2993 (synthetic exendin-4) lowered fasting glucose concentrations through suppression of glucagon and dose-dependent insulinotropism in patients with type 2 diabetes (abstract). Diabetes 2002, 51(Suppl. 2): A104.
69. Fineman, M.S., Bicsak, T., Shen, L. et al. AC 2993 (synthetic exendin-4) added to existing metformin (MET) and/or sulfonylurea (SFU) treatment improved glycemic control in patients with type 2 diabetes (DM2) during 28 days of treatment (abstract). Diabetes 2002, 51(Suppl. 2): A85.
70. Trautmann, M.E., Kapitza, C., Mace, K.F., Patterson, B., Hompesch, M. and Heise, T. LY 307161 SR, a sustained release formulation of a GLP-1 analog, is suitable for once daily administration in patients with type 2 diabetes (abstract). Diabetes 2002, 51(Suppl. 2): A135.
71. Kapitza, C., Trautmann, M., Heise, T., Heinemann, L. and Patterson, B. Daily administration of LY307161 (GLP-1 analog) normalizes blood glucose on type 2 diabetes (abstract). Diabetes 2002, 51(Suppl. 2): A84.
72. Lawrence, B., Wen, S.Y., Jette, L., Thibaudeau, K. and Castaigne, J.-R CJC-1131, the novel long-acting GLP-1 analogue, delays gastric emptying and demonstrates safety and tolerability in preclinical testing (abstract). Diabetes 2002, 51(Suppl. 2): A84.
73. Bridon, D.P., Thibaudeau, K., L'Archeveque, B.P., Pham, K., Robitaille, M.F., Drucker, D.J. et al. The long-acting GLP-1 agonist CJC 1131 exhibits high potency and extended pharmacokinetics in vivo (abstract). Diabetes 2002, 51(Suppl. 2): A93.
74. Thibaudeau, K., Smith, D.C., Jette, L. et al. Development and characterization of long-acting degradation resistant GLP-1-DAC compounds for the treatment of type 2 diabetes (abstract). Diabetes 2002, 50(Suppl. 2): A116.
75. Deacon, C.F., Highes, T.E. and Holst, J.J. Dipeptidyl peptidase IV inhibition potentiates the insalinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998, 47: 764-9.
76. Deacon, C.F., Danielsen, P., Klarskov, L., Olesen, M. and Holst, J.J. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of G1P and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 2001, 50: 1588-97.
77. Rothenberg, P., Kalbag, J., Smith, H. et al. Treatment with a DPP-IV inhibitor, NVP-DPP728, increases prandial intact GLP-1 levels and reduces glucose exposure in humans (abstract). Diabetes 2000, 49(Suppl. 1): A39.
78. Vitsbøll, T., Krarup, T., Madsbad, S. and Holst, J.J. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med 2001, 18: 144-9.
79. Nauck, M.A., Heimesaat, M.M., Behle et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87: 1239-46.
80. Egan, J., Clocquet, A.R. and Elahi, D. Insulinotropic effect of exendin-4 in humans (abstract). Diabetologia 1999, 42(Suppl. 1): A41.
81. Fineman, M., Young, A., Gaines, E. and Prickett, K. Dose-response for postprandial glucose-lowering effect of synthetic exendin-4 (AC2993) in subjects with type 2 diabetes (abstract). Diabetes 2000, 49(Suppl. 1): A106.
82. Kolterman, O., Gottlieb, A., Prickett, K., Gaines, E. and Young, A. Dose-response for inhibition of glucagon secretion and gastric emptying by synthetic exendin-4 (AC2993) in subjects with type 2 diabetes (abstract). Diabetes 2000, 49(Suppl. 1): A114.
83. Young, A., Gottlieb, A., Fineman, M. and Kolterman, O. Measurements of satiety and fullness following a sustacal challenge in type 2 diabetic subjects administered synthetic exendin-4 (AC2993) (abstract). Diabetologia 1999, 42(Suppl. 1): A40.
84. Kolterman, O., Fineman, M., Gottlieb, A., Petrella, E., Pricket, K. and Young, A. AC2993 (synthetic exendin-4) lowered postprandial plasma glucose concentrations in people with type 2 diabetes (abstract). Diabetologia 1999, 42(Suppl. 1): A41.
85. Levy, J.C., Maksoud, H., Barrow, B.A. and Sutton, P.J. Subcutaneous exendin-4 improves daytime glucose exposure by reducing postprandial glucose increment in diet treated type 2 diabetic patients (abstract). Diabetes 2000, 49(Suppl. 1): A115.
86. Maksoud, H., Barrow, B.A., Manley, S.E. and Levy, J.C. Subcutaneous exendin-4 reduces basal glucose and postprandial glucose increment and improves beta cell function in sulphonylurea treated type 2 diabetic subjects (abstract). Diabetes 2000. 49(Suppl. 1): A116.
87. Taylor, K., Kim, D., Bicsak, T. et al. Continuous subcutaneous infusion of AC 2993 (synthetic exendin-4) provides sustained day-long glycemic control to patients with type 2 diabetes (abstract). Diabetes 2002, 51(Suppl. 2): A85.
88. Buse, J., Fineman, M., Gottlieb, A., Gaines, E. and Kolterman, O. Effect of five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes (abstract). Diabetes 2000, 49(Suppl. 1).
89. Demuth, H.-U., Hoffmann, T., Glund, K. et al. Single dose treatment of patients by the DPIV inhibitor P32/98 (abstract). Diabetes 2000, 49(Suppl. 1): A102.
90. Åhren, B., Simonsson, E., Larsson, H. et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25: 869-75.
91. Bregenholdt, S., Møldrup, A., Blume, N., Bjerre Knudsen, L. and Petersen, J.S. The GLP-1 analogue, NN2211, inhibits free fatty acid-induced opoptosis in primary rat beta-cells (abstract). Diabetologia 2001, 44(Suppl. 1): A19.
92. Bregenholdt, S., Moldrup, A.B., Knudsen, L. and Petersen, J.S. The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat beta-cells (abstracts). Diabetes 2001, 50(Suppl. 1): A31.
93. Rolin, B., Carr, R. and Knudsen, L.B. Efficacy of the long-acting GLP-I derivative NN2211 in diabetic db/db mice (abstract). Diabetes 2000, 49(Suppl. 1): A227.
94. Larsen, M.O., Gotfredsen, C.F., Rolin, B., Wilken, M. and Bjerre Knudsen, L. NN2211, a long-acting GLP-1 derivative, decreases blood glucose and stimulates beta-cell proliferation in db/db mice (abstract). Diabetologia 2001, 44(Suppl. 1): A197.
95. Larsen, M.O., Rolin, B., Wilken, M., Carr, R.D. and Bjerre Knudsen, L. NN2211, a GLP-1 derivative, has a long lasting blood glucose lowering effect in db/db mice: A comparison with exendin-4 (abstract). Diabetes 2001. 50(Suppl. 1): A312.
96. Larsen, P.J., Tang-Christensen, M. and Knudsen, L.B. Systemic administration of the long-acting GLP-1 analogue, NN2211, induces lasting and reversible loss of body adiposity, (abstract). Diabetologia 2000, 43(Suppl. 1): A144.
97. Sturis, J., Jappe, M.B., Knudsen, L.B. et al. Long-acting GLP-1 derivative NN2211 markedly slows the development of diabetes in the male Zucker diabetic fatty rat (abstract). Diabetes 2000, 49(Suppl. 1): A228.
98. Rolin, B., Gotfredsen, C., Sturis, J. et al. NN2211, a protracted GLP-1 derivative, ameliorates glycaemia and reduces triglyceride levels in pre-diabetic ZDF rats (abstract). Diabetes 2001, 50(Suppl. 1): A312.
99. Rømer, J., Pedersen, K.E., Jørgensen, B. et al. Effect of the long-acting GLP-1 derivative NN2211 in 60% pancreatectomized rats (abstract). Diabetes 2001, 50(Suppl. 1): A312.
100. Ribel, U., Hvidt, M., Larsen, M.Ø., Rolin, B., Wilken, M. and Knudsen, L.B. Glucose lowering effect of the protracted GLP-1 derivative, NN2211, in the beta cell reduced minipig (abstract). Diabetologia 2000, 43(Suppl. 1): A145,
101. Hansen, B.C., Bjenning, C. and Bjerrre Knudsen, L. Sustained appetite suppression and weight loss in obese rhesus monkeys treated with a long-acting GLP-1 derivative, NN2211 (abstract). Diabetologia 2001, 44(Suppl. 1): A196.
102. Parkes, D., Gedulin, B., Smith, P. and Young, A. Effect of exendin-4 on glucagon secretion in lean and obese Zucker (ZDF) rats (abstracts). Diabetes 2001, 50(Suppl. 1): A313.
103. Tourrel, C., Bailbe, D., Meile, M.-J., Kergoat, M. and Portha, B. Glucagon-like peptide-1 (GLP-1) or exendin-4 administration enhances regeneration of the beta-cell mass in streptozotocin-treated newborn rats (abstract). Diabetes 2000, 49(Suppl. 1): A257.
104. Tourrel, C., Bailbe, D., Meile, M.-J., Kergoat, M. and Portha, B. Glucagon-like peptide-1 (GLP-1) of exendin-4 treatment limited to the pre-diabetic period limits the progression to overt NIDDM in the adult GK rat (abstract). Diabetes 2001, 50(Suppl. 1): A3339.
105. Bonner-Weir, S. Increased beta-cell mass as mechanism of ameliorated glucose tolerance after exendin-4 treatment in diabetic pancreatectomized rats (abstract). Diabetes 1999, 48(Suppl. 1): A20.
106. Nolan, A.L., Sennitt, M.V., Whittle, E.B., Stocker, C.J. and Cawthorne, M.A. Acute and chronic effects of exendin-4 on glycaemic control and food intake in diabetic mice (abstract). Diabetologia 2000, 43(Suppl. 1): A148.
107. Bhasvar, S., Jodka, C., Smith, P., Gedulin, B. and Young, A. Continuous infusion of exendin-4 lowered HbA1c at least as effectively as twice daily injections in diabetic Zucker fatty (ZDF) rats (abstract). Diabetologia 2001, 44(Suppl. 1): A198.
108. Smith, P., Young, A. and Gedulin, B. Exendin-4 injections ameliorated progression of fasting hyperglycemia and elevation of HbA1c in diabetic fatty Zucker (ZDF) rats (abstract). Diabetes 2001, 50(Suppl. 1): A197.
109. Ribel, U., Bentsen, E., Rømer. J., Jørgensen, B., Rothe, R, Pedersen, K.E. et al. Dipeptidyl peptidase IV inhibition promotes differentiation of new beta cells in 60% pancreatectomized rats (abstract). Diabetologia 2001, 44(Suppl. 1): A 192.
110. Freyse, E.-J., Knospe, S., Glund, K. and Demuth, H.U. Dosage of a dipeptidyl peptidase IV (DP IV) inhibitor and timing of its administration to improve glucose tolerance in rats (abstract). Diabetes 1999, 48(Suppl. 1): A355.
111. Demuth, H.-U., Freyse, E.-J., Ber, S., Heinke. P., McIntosh, C.C.H. and Pederson, R.A. Prodrugs of DP IV inhibitors strongly improved incretin-mediated glucose tolerance (abstract). Diabetes 2000, 49(Suppl. 1): A228.
112. Freyse, E.-J., Berg, S., Glund, K., Heinke, P. and Demuth. H.-U. Metabolic effects of subchronic oral application of the DPPIV-inhibitor P32/98 and a P32/98 prodrug in diabetic Zucker rats (fa/fa) (abstract). Diabetes 2001, 50(Suppl. 1).
113. Stocker, C., Wargent, E., Subramaniam, A., Demuth, H.-U., Sennitt, M. and Cawthome, M.A. The dipeptidyl peptidase inhibitor P32/98 improves glucose tolerance in diabetic ZDF rats (abstract). Diabetes 2001, 50(Suppl. 1): A522.
114. Pospisislik, J.A., Stafford, S., Demuth, H.-U., McIntosh, C.H.S. and Pederson, R.A. Long-term DP IV inhibitor (P32/98) treatment causes sustained improvements in glucose tolerance, insulin sensitivity, and hyperinsulinemia in fa/fa Zucker rats (abstract). Diabetes 2001, 50(Suppl. 1): A311.
115. Balkan, B., Kwasnik, L., Battle, B. and Li., X. Sustained improvement of glucose tolerance by DPP-IV inhibition after chronic treatment with NVP-DPP728 (abstract). Diabetologia 1999, 42(Suppl. 1): A41.
116. Balkan, B., Li, X. and Kwasnik, L. GLP-I secretion and beneficial effects of DPP-IV inhibition are increased by insulin resistant rats (abstract). Diabetologia 2000, 43(Suppl. 1): A148.
117. Mitani, H., Takimoto, M., Balkan, B., Hughes, T. and Kimura, M. Lack of dipeptidyl peptidase IV (DPP-IV) activitv prevents the development of impaired glucose tolerance in rats fed a high fat diet (abstract). Diabetes 2000, 49(Suppl. 1): A286.
118. Dunning, B.E., Deacon, R., Paladini, S. and Hughes, T. Six week treatment with a DPP-IV inhibitor, NVP-DPP728, prevents metabolic deterioration in overfed cynomolgus monkeys (abstract). Diabetes 2000, 49(Suppl. 1).
119. Elm, T., Ribel, U., Bentsen, E., Due, A.-L., Deacon, C.F., Wagtman, N. et al. CD26 knockout mice have improved glucose tolerance and elevated levels of intact incretin hormones (abstract). Diabetologia 2001, 44(Suppl. 1).